Dr Bauer is a graduate of Johann Wolfgang Goethe University in Frankfurt (Biology) and holds a Ph.D. in Molecular Biology.
After spending four years as a research scientist at the Nestlé Research Center in Lausanne, Dr Bauer joined the R&D Center of Lesaffre International, the world leader in the baker’s yeast market, where he was Head of the Molecular Biology and Genetics Team. In 2000 he joined Axaron Bioscience AG in Heidelberg, a joint venture of BASF and Lynx Therapeutics from where he moved on to Gentana GmbH, a biotech company providing gene expression analysis services based on its proprietary technology platform. After acting as CEO of Gentana for two years, Dr Bauer joined EMBL Enterprise Management Technology Transfer GmbH, a 100% subsidiary of the European Molecular Biology Laboratory as Business Development Manager. As of May 2011 he is appointed as Deputy Managing Director of EMBLEM and responsible for Business Development. Dr Bauer is alumnus of the Chemical Industry Fund within the German Chemical Industry Association and the St. Gallen Business School.
Currently member of Boehringer Ingelheim’s Business Development & Licensing Team, and based in Germany, Julie is responsible for leading contract negotiations and managing strategic alliances (CAM) that support the scientific and business development objectives of the Innovation Unit at Boehringer Ingelheim. In this role and throughout her career, Julie has proactively and effectively interacted with key stakeholders of the life sciences ecosystem to drive the establishment of strategic alliances and partnerships to progress innovative science towards application. Prior to joining Contracts and Alliance Management, Julie was Head, Research Beyond Borders (RBB) Project Office and Strategic Partnering at Boehringer Ingelheim, where she fostered the development and implementation of new science project proposals and their enablement through external sources of innovation. Prior to joining RBB, Julie was Director, Corporate Development at Genome Canada, where she developed and lead strategic international partnerships with an emphasis on public-private partnerships.
Earlier in her career, Julie supported Boehringer’s Infectious Disease Research efforts at its Canadian research site, in her role as Head, Scientific Administration and External Scientific Affairs. Julie has also acted as consultant, working with inventors, academic institutions, start-up companies, investors and other stakeholders, on strategic planning including business development and partnering initiatives, commercialization strategies, and licensing and due diligence of new technologies with both high applied and commercial potential. Julie graduated with an M.Sc in Immunology and Virology from Institut Armand-Frappier, Quebec, Canada.
Thomas Hegendörfer is the New Ventures Lead for Germany at Johnson & Johnson Innovation. He is responsible for identifying collaboration opportunities and forging partnerships between the London Innovation Center and German scientists, innovators, and entrepreneurs. Before joining Johnson & Johnson, Thomas was Head of Business Development at Lead Discovery Center GmbH (LDC), a leading translational center in Germany advancing academic drug discovery into application. In this position, he was responsible for closing numerous partnerships and licensing deals with partners from the pharmaceutical industry and biotech companies across major indications. Prior to joining the LDC he worked in Licensing and Patent Management at Max-Planck-Innovation. Thomas graduated with an M.Sc in Molecular Medicine from Imperial College, London, and holds a B.Sc. degree in Molecular Biotechnology from the Technical University of Munich.
Thomas Hesterkamp is heading an office of the product development unit of the German Center for Infection Research (DZIF). Thomas serves various project steering committees of DZIF (more generally BMBF) funded projects and provides access to early and informal scientific and regulatory advice through the competent authorities. Thomas also serves the technology transfer committee of DZIF and the TT offices of the DZIF member institutions. In doing so DZIF wishes to advance the much-needed product related projects to a stage of value inflection, ready for external partnerships and innovation. Previously Thomas held scientific and managerial positions in the private sector, at Evotec and Arpida. Thomas is a trained human biologist.
Karolina is the commercialization manager at the Centre of Technology and Knowledge Transfer (CTKT), University of Pardubice. She holds her degree in chemistry and chemical technology from Faculty of Chemical Technology. She has been responsible for negotiations and licensing to the industry, has been directly involved in evaluation and development of the proof-of-concept projects including the intellectual property protection strategy and management of their commercialization activities (particularly in the area of chemical and pharmaceutical technologies, new materials, biochemistry and diagnostics). Lately she has participated in raising nearly 2 million GBP from public funds for proof-of-concept activities and education and mentorship to researchers in academia in the area of intellectual property protection and evaluation, marketing and business development. Karolina has also gained her expertise based on the robust training at the world leading technology transfer entities or platforms (Cambridge Enterprise, AUTM, London Business School, ETPL A*STAR, IPI Singapore, etc.). Recently she has initiated the cooperation with Stanford Medical School and their SPARK Programme in Translational Research.
John has held his current position of Associate Director of Business Development for over 3 years. He leads a team responsible for identifying early stage targets, small molecules and monoclonal antibodies for MRCT’s drug discovery group, The Centre for Therapeutics Discovery which was established in 2006. He and the BD team then lead negotiations and the licensing of mature programmes to industry. John was responsible for MRCT’s first small molecule deal with a US Pharma as well as securing several antibody engineering contracts.
John received his PhD from the Department of Thoracic Medicine, National Heart and Lung Institute, London, and gained a BSc (Hons) 2.1 Pharmacology from King’s College London, and a BSc (Gen) Pharmacology and Chemistry from University College Dublin. Prior to joining MRCT his previous work experience included 5 years Postdoctoral at Cancer Research UK, (previously Imperial Cancer Research Fund), London, UK and Department of Pharmacology, University of South Alabama College of Medicine, Mobile, Alabama, USA. His previous role within MRCT was as Associate Director of Intellectual Property and Business Development where he focused on intellectual property management, marketing and business development. For 10 years he managed on behalf of the MRC, the University of Dundee/MRC/Pharma consortium (DSTT) of which GSK, Pfizer, J&J, Merck Serono and AZ are current members.
Sarah is Head of Licensing at Bayerische Patentallianz, the Technology Transfer Office of 28 Bavarian Universities and Universities of Applied Sciences.
In her role as Head of Licensing she is responsible for scientific and business evaluation of new technologies and ideas and lead negotiations of early stage programs. Furthermore she manages partnerships with Start-ups, SMEs and Pharma industry. Sarah holds a Diploma in Chemistry and received her PhD in Organic/Medicinal Chemistry at the University of Hamburg. In this period she was responsible for supervising a research team in the field of oncology. In her previous role as a Licensing Manager within Bayerische Patentallianz she focused on IP Management, Marketing and Business Development.
Currently Director of International Development at FIST S.A. (French Technology Transfer Company of the CNRS), Stéphane Mottola has 20 years experience in pharmaceuticals and biotechnology. For more than a decade, she has been involved in the evaluation and selection of innovative technologies, the management of the industrial property strategy, and the negotiation of strategic deals, such as licences and collaboration agreements with Start-up, SME and Big pharma.
Previously to FIST S.A., Stéphane Mottola worked as a Patent attorney in Paris. She has also well rounded experience of international organization as she was for three years examiner for pharmaceuticals at the European Patent Office in Munich. After that, she joined the Food and Agricultural Organization of the United Nations in Roma, where she was an associate expert within the Nutrition Division. She enhanced her international culture by working one year in Los Angeles within the marketing department of an US technology company.
Stéphane Mottola is Doctor in Pharmacy, member of the LES; she is from French mother tong and speaks fluently English, German and Italian.
Torsten Porwol earned a Diploma in Chemistry and a Dr. rer. nat. from Ruhr-University in Bochum, Germany with specialization in Physical Chemistry. Work and studies included stays at the Synchrotron research facility in Berlin and the University of Sussex. Torsten joined the Max Planck Institute for molecular Physiology in Dortmund after his PhD degree focusing on cancer research. Interdisciplinary research activities included collaborations with University Hospitals in Europe resulting in over 35 articles in peer review journals covering Chemistry, Physics, Biology and Medicine.
Torsten has served as a Manager for Professional Services of SGI in Norway and as Sales Manager in the Omya Corporation in Norway. In 2006 Torsten joined BTO, the technology transfer office in Bergen, as a Senior Business Developer. At BTO he handled IP and negotiated partnering agreements in a variety of ventures. He has expertise as steering committee member in research corporations and monetization.
Stefanie Possekel spent more than 10 years in the pharmaceutical and biotech industry and has broad experience in in- and outlicensing of clinical and preclinical projects. In particular, she successfully worked on a number of major research and development collaborations with academic institutions.
She joined Ascenion in October 2012 from Novartis, where she served as Director Strategic Alliances with global responsibilities for the Musculoskeletal Disease Area and Oncology. Prior to that she worked as Director Business Development at Santhera Pharmaceuticals, a Swiss-based specialty pharmaceutical company for orphan neuromuscular diseases.
Stefanie studied Biology at the Philipps University Marburg with a specific focus on Microbiology, Immunology, Genetics and Biochemistry and received her PhD in 1995. During her thesis she spent time at the Biocenter in Basel and worked closely with researchers at the Institute de Myologie in Paris, France. After her PhD, Stefanie spent 3 years in the Bay Area (California), working as a freelance science writer and scientific consultant to Affymetrix.
After graduating in Biochemistry from the Ernst-Moritz-Arndt University in Greifswald, Germany Julie joined the group of Martin Groschup at the Friedrich Loeffler Institute in Germany to earn a PhD on the topic of Mad Cow Disease. After her PhD she moved to Calgary, Canada as a postdoc first in Jan Braun’s lab and followed by a stay in Peter K Stys’s lab. In both labs she focused on neurodegenerative diseases using molecular and biochemical methods and state of the art imaging techniques in the Stys lab. After returning to Europe in 2014 she started another postdoc at the IOCB in Prague focusing on cancer research and ultimately joined the TTO team full time in January 2016.
In the IOCB-TTO team Julie focuses mainly on projects related to cancer research and is involved in PR and communication.
Dr Laura Spinardi graduated in Biology at the University of Turin and holds a PhD in Neurobiology under the joint supervision of the New York University Medical Center; she then worked as a postdoctoral fellow at the European Molecular Biology Laboratory in Heidelberg and Monterotondo (Rome). After a decade of successful scientific and professional achievements in the USA, France and Germany as a research scientist, she joined in 2007 the Ca’ Granda IRCCS Foundation - Milan Policlinico Hospital, a public medical and research center, where she founded the Technology Transfer Office. She is currently managing the Policlinico TTO and is in charge for scouting, patenting, transferring and educational activities; she is Board Member of Netval, the Italian Network of Technology Transfer Offices of Universities and Research Organizations.
Dr Siegling is a Patent and Licence Manager in the Life Science area at aws - Austria Wirtschaftsservice GmbH, Austria’s specialised bank for business promotion. Her activities and expertise includes technology transfer, evaluation of new technologies and ideas, deal making, business intelligence, and conducting due diligence. She is a Certified Licensing Professional and holds a Doctor of Natural Sciences in Pharmaceutical Chemistry from the Leipzig University, Germany.
Prior to joining aws Dr Siegling was the Chief Scientific Officer at two different biotechnology companies (Mixis France S.A. in Paris and Eucodis GmbH in Vienna) where she was responsible for the company’s research program and patent, licencing and commercialization planning activities. Prior to this she was a research scientist and project manager for the pharmaceutical company Bayer AG and a post-doc at the Max Planck Society in Erlangen, Germany and the Charité in Berlin, Germany and the LSUMC in New Orleans, USA.
Matthias Versele is responsible for the identification and selection of new investment opportunities from academic and industrial partners across therapeutic areas and for implementing and driving a sound drug discovery approach for the selected projects in collaboration with CD3’s partners. Prior to joining CD3 in 2017, Matthias was Associate Scientific Director of the Oncology Discovery Group at Janssen (a Johnson and Johnson company). He was a core member of the hematologic disease area and responsible for identifying and validating novel targets, and running discovery projects in B-cell malignancies, multiple myeloma and myeloid leukemias, from hit identification to delivering a clinical candidate. In addition, he was the preclinical lead for Janssen during the clinical development of the covalent BTK inhibitor, ibrutinib (now marketed as Imbruvica®), where he contributed to the identification of clinically meaningful mechanisms of primary and acquired resistance, and the subsequent initiation of follow-on discovery projects. Prior to joining Janssen in 2006, he was a Human Frontier Science Program post-doctoral fellow at UC Berkeley (CA) working on the coordination of septin filament assembly with cell cycle progression and cell division. He earned his PhD in biochemistry in 2000 at the University of Leuven (Belgium) studying nutrient sensing and signaling mechanisms in yeast.
Dr Jürgen Walkenhorst studied biology/molecular biology in Osnabrück and Aberdeen (UK). After his diploma thesis at the EMBL in Heidelberg, he worked at Genentech, Inc. (USA). He undertook his PhD-thesis at the Max-Planck-Institute for Developmental Biology in Tübingen. He joined Cellzome AG (Heidelberg) as the first employee where he was instrumental in setting up the company and was later responsible for IP-issues. After a stint in the patent department of Baxter AG in Vienna, he changed to technology transfer. At Austria Wirtschaftsservice GmbH, Vienna, he was responsible for inventions in the field of biotechnology and medical devices being developed at Austrian universities. In 2007 he moved to PROvendis, where he currently serves as the head of the Life sciences team.